BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
July 22 2024 - 6:45AM
MAINZ, Germany, July 22, 2024 (GLOBE
NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”) will announce its financial results for the second
quarter 2024 on Monday, August 5, 2024. Additionally, the Company
will host a conference call and webcast that day at 8:00 a.m. EDT
(2:00 p.m. CEST) for investors, financial analysts and the general
public to discuss its financial results and provide a corporate
update.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a PIN will be provided. It is recommended to register
at least one day in advance. The slide presentation and audio of
the webcast will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page in the Investor Relations section of the Company’s website at
www.BioNTech.com. A replay of the webcast will be made available
shortly after the call and archived on the Company’s website for 30
days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is
a global next generation immunotherapy company pioneering novel
therapies for cancer and other serious diseases. BioNTech exploits
a wide array of computational discovery and therapeutic drug
platforms for the rapid development of novel biopharmaceuticals.
Its broad portfolio of oncology product candidates includes
individualized and off-the-shelf mRNA-based therapies, innovative
chimeric antigen receptor (CAR) T cells, several protein-based
therapeutics, including bispecific immune checkpoint modulators,
targeted cancer antibodies and antibody-drug conjugate (ADC)
therapeutics, as well as small molecules. Based on its deep
expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing
multiple mRNA vaccine candidates for a range of infectious diseases
alongside its diverse oncology pipeline. BioNTech has established a
broad set of relationships with multiple global and specialized
pharmaceutical collaborators, including Biotheus, DualityBio, Fosun
Pharma, Genentech, a member of the Roche Group, Genevant, Genmab,
MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit
www.BioNTech.com.
CONTACTS
Investor RelationsVictoria Meissner, M.D.+1 617 528
8293Investors@biontech.de
Media RelationsJasmina Alatovic+49 (0)6131 9084
1513Media@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Nov 2023 to Nov 2024
